Caristo Diagnostics

medical devices

About

Caristo Diagnostics is a UK-based medical imaging and biotechnology company focused on cardiovascular disease diagnostics and risk prediction. Founded in June 2018 as a spin-out from the University of Oxford, Caristo utilizes advanced imaging biomarkers and artificial intelligence to enhance the early detection and management of heart disease. The company's flagship product, CaRi-Heart®, is an AI-powered platform that analyzes cardiac CT scans to identify coronary inflammation and plaque. This technology helps physicians proactively detect patients at risk of acute cardiac events, enabling earlier interventions. Caristo's diagnostic services are adopted by hospitals and healthcare providers, enhancing cardiovascular risk prediction alongside traditional assessment methods. Caristo Diagnostics has experienced significant growth, particularly in 2024, with a notable increase in the use of its technology. The company collaborates with prominent healthcare organizations, including the NHS and Cleveland Clinic UK, and has expanded its presence internationally with a new office in the U.S.

Technologies

Route 53 Amazon SES Outlook Zendesk Ubuntu Apache WordPress.org Google Tag Manager Bootstrap Framework Mobile Friendly Google Maps AI

Keywords

medical imaging artificial intelligence machine learning cardiology heart disease fai healthcare medicine clinical trials core lab cloud medical device medical equipment manufacturing clinical trial data personalized cardiac risk score coronary artery inflammation biomarker personalized medicine in cardiology non-invasive inflammation detection medical devices personalized risk score medical equipment and supplies manufacturing cardiac ct ai atherosclerosis imaging b2b plaque burden assessment risk prediction plaque analysis software inflammation quantification in ccta ai-driven cardiac risk assessment fai-score

Location

234 Botley Road, Oxford, England, United Kingdom, OX2 0HP

Related Companies

Companies in the same industry